Glycosaminoglycans reduced inflammatory response by modulating toll-like receptor-4 in LPS-stimulated chondrocytes

Glycosaminoglycans reduced inflammatory response by modulating toll-like receptor-4 in LPS-stimulated chondrocytes
复制标题

DOI:
10.1016/j.abb.2009.09.017
复制
发表时间:
2009-11-01
影响因子:
3.9
通讯作者:
Calatroni, Alberto
Calatroni, Alberto
中科院分区:
生物学3区
文献类型:
--
作者:
Campo, Giuseppe M.;Avenoso, Angela;Calatroni, Alberto

文献摘要

被引文献

相似文献

脂多糖(LPS)介导的toll样受体-4 (TLR-4)复合物的激活可诱导特异性信号通路,如髓样分化主要反应蛋白-88 (MyD88)和肿瘤坏死因子受体相关因子-6 (TRAF-6),涉及nf - κ B的激活。由于先前的数据报道透明质酸(HA)和硫酸肝素(HS)可能与TLR-4相互作用,本研究的目的是研究糖胺聚糖(GAGs)是否可能在lps诱导的小鼠软骨细胞炎症因子模型中调节TLR-4受体。LPS刺激上调了所有炎症参数。GAG治疗产生多种作用:HA仅在高剂量时降低MyD88、TRAF-6水平和NF-kappa B激活,抗炎作用很低;硫酸软骨素(C4S)和硫酸软骨素(6-硫酸软骨素)显著抑制MyD88、TRAF-6和NF-kappa B的激活、炎症因子和诱导型一氧化氮合酶;HS与C4S一样,显著降低MyD88、TRAF-6、nf - κ B及炎症反应。特异性TLR-4阻断抗体证实TLR-4是GAG作用的靶点。(C) 2009爱思唯尔公司版权所有。
Lipopolysaccharide (LPS)-mediated activation of toll-like receptor-4 (TLR-4) complex induces specific signaling pathways, such as the myeloid differentiation primary response protein-88 (MyD88) and the tumor necrosis factor receptor-associated factor-6 (TRAF-6), involving NF-kappa B activation. As previous data reported that hyaluronan (HA) and heparan sulfate (HS) may interact with TLR-4, the aim of this study was to investigate whether glycosaminoglycans (GAGs) may modulate the TLR-4 receptor in a model of LPS-induced inflammatory cytokines in mouse chondrocytes. LPS stimulation up-regulated all inflammation parameters. The GAG treatment produced various effects: HA reduced MyD88 and TRAF-6 levels and NF-kappa B activation at the higher dose only, and exerted a very low anti-inflammatory effect; chondroitin-4-sulfate (C4S) and chondroitin-6-sulfate significantly inhibited MyD88, TRAF-6 and NF-kappa B activation, the inflammation cytokines, and inducible nitric oxide synthase; HS, like C4S, significantly reduced MyD88, TRAF-6, NF-kappa B and inflammation. Specific TLR-4 blocking antibody confirmed that TLR-4 was the target of GAG action. (C) 2009 Elsevier Inc. All rights reserved.